Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Waldenstrom Macroglobulinemia 5Recurrence 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 4Lymphoma 2Leukemia 2B-cell Malignancies 2Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia × zanubrutinib × Clear all
NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

BeiGene

Phase 1 Completed
119 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeiGene

Phase 1 Completed
75 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡